

.....
(Original Signature of Member)

109TH CONGRESS
1ST SESSION

H. R. _____

To reauthorize the Office of National Drug Control Policy Act and to establish minimum drug testing standards for major professional sports leagues.

IN THE HOUSE OF REPRESENTATIVES

Mr. TOM DAVIS of Virginia (for himself, Mr. WAXMAN, Mr. SOUDER, and Mr. CUMMINGS) introduced the following bill; which was referred to the Committee on _____

A BILL

To reauthorize the Office of National Drug Control Policy Act and to establish minimum drug testing standards for major professional sports leagues.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. TABLE OF CONTENTS.**

4 The table of contents for this Act is as follows:

Sec. 1. Table of contents.

TITLE I—REAUTHORIZATION OF OFFICE OF NATIONAL DRUG
CONTROL POLICY ACT

Sec. 101. Short title.



Sec. 102. Repeal of termination provision.

Sec. 103. Authorization of appropriations.

TITLE II—CLEAN SPORTS ACT OF 2005

Sec. 201. Addition of minimum drug testing standards to Office of National Drug Control Policy Act.

1 **TITLE I—REAUTHORIZATION OF**
2 **OFFICE OF NATIONAL DRUG**
3 **CONTROL POLICY ACT**

4 **SEC. 101. SHORT TITLE.**

5 This title may be cited as the “Office of National
6 Drug Control Reauthorization Act”.

7 **SEC. 102. REPEAL OF TERMINATION PROVISION.**

8 Section 715 of the Office of National Drug Control
9 Policy Reauthorization Act of 1998 (Public Law 105–277;
10 21 U.S.C. 1712) is repealed, and the law shall read as
11 if such section was never in effect.

12 **SEC. 103. AUTHORIZATION OF APPROPRIATIONS.**

13 Section 714 of such Act (21 U.S.C. 1711) is
14 amended—

15 (1) by striking “title,” and inserting “subtitle,
16 except activities for which amounts are otherwise
17 specifically authorized by this subtitle,”; and

18 (2) by striking “1999 through 2003” and in-
19 serting “2006 through 2010”.



1 “(2) Experts estimate that over 500,000 teen-
2 agers have used performance-enhancing substances,
3 which medical experts warn can cause a litany of
4 health problems for individuals who take them, in
5 particular children and teenagers.

6 “(3) The adverse health effects caused by
7 steroids and other performance-enhancing sub-
8 stances include stunted growth, scarring acne, hair
9 loss, dramatic mood swings, hormonal and metabolic
10 imbalances, liver damage, a higher risk of heart dis-
11 ease and stroke later in life, as well as an increased
12 propensity to demonstrate aggressive behavior, com-
13 mit suicide, and commit crimes.

14 “(4) Professional athletes are role models for
15 young athletes and influence the behavior of children
16 and teenagers.

17 “(5) Congressional testimony by parents of mi-
18 nors who used performance enhancing drugs, as well
19 as medical and health experts, indicates that the ac-
20 tual or alleged use of performance-enhancing sub-
21 stances by professional athletes results in the in-
22 creased use of these substances by children and
23 teenagers.

24 “(6) Surveys and studies suggest a connection
25 between the actual or alleged use of performance-en-



1 hanging substances by college and professional ath-
 2 letes and the increased use of these substances by
 3 children and teenagers.
 4 “(7) The real or perceived tolerance of the use
 5 of performance-enhancing substances by professional
 6 athletes has resulted in both increased pressure on
 7 children and teenagers to use performance-enhanc-
 8 ing drugs in order to advance their athletic careers
 9 and to professional sports loss of integrity.
 10 “(8) The adoption by professional sports
 11 leagues of strong policies to eliminate the use of per-
 12 formance-enhancing substances would result in the
 13 reduced use of these substances by children and
 14 teenagers.
 15 “(9) Minimum drug testing standards for pro-
 16 fessional sports established by Federal law would en-
 17 sure the adoption of strong policies to eliminate the
 18 use of performance-enhancing substances in profes-
 19 sional sports.
 20 “(10) Minimum drug testing standards for pro-
 21 fessional sports established by Federal law would
 22 help return integrity to professional sports.
 23 “(11) Congress has for several years expressed
 24 a strong interest in the problem of the role of per-



1 performance-enhancing drugs in professional sports and
2 other levels of sports.

3 “(12) Congress has for several years regulated
4 the use of anabolic steroids and other performance-
5 enhancing substances.

6 “(13) Recent Federal laws regulating the use of
7 anabolic steroids and other performance-enhancing
8 substances were enacted in large part to reduce the
9 prevalence of these substances in sports.

10 “(14) Congress has for several years regulated
11 both professional and amateur sports.

12 “(b) PURPOSE.—The purpose of this subtitle is to
13 protect the integrity of professional sports and the health
14 and safety of athletes generally by establishing minimum
15 standards for the testing of steroids and other perform-
16 ance-enhancing substances by professional sports leagues.

17 **“SEC. 723. DEFINITIONS.**

18 “In this subtitle:

19 “(1) ANTI-DOPING CODE.—The term ‘anti-
20 doping code’ means the doping control standards es-
21 tablished in the United States Anti-Doping Agency
22 Protocol for Olympic Movement Testing (excluding
23 substances or methods prohibited in a particular
24 sport, as defined in such protocol).



1 “(2) COMMISSION.—The term ‘Commission’
2 means the Federal Trade Commission.

3 “(3) DIRECTOR.—The term ‘Director’ means
4 the Director of the Office of National Drug Control
5 Policy.

6 “(4) MAJOR PROFESSIONAL LEAGUE.—The
7 term ‘major professional league’ means Major
8 League Baseball, the National Basketball Associa-
9 tion, the National Football League, and the National
10 Hockey League or any successor organization to
11 those leagues.

12 “(5) OFF-SEASON.—The term ‘off-season’
13 means the period of time in each calendar year out-
14 side of the season of play for each major profes-
15 sional league.

16 “(6) PROFESSIONAL ATHLETE.—The term ‘pro-
17 fessional athlete’ means an individual who competes
18 in a major professional league.

19 “(7) PROFESSIONAL GAME.—The term ‘profes-
20 sional game’ means any game held in the United
21 States between any professional teams of a major
22 professional league.

23 “(8) PROHIBITED METHOD OR SUBSTANCE.—



1 “(A) PROHIBITED METHOD.—The term
2 ‘prohibited method’ means a method listed and
3 described in the Anti-Doping Code.

4 “(B) PROHIBITED SUBSTANCE.—The term
5 ‘prohibited substance’ means a substance listed
6 and described in the Anti-Doping Code.

7 “(C) PERIOD OF PROHIBITION.—A sub-
8 stance prohibited in-competition by the Anti-
9 Doping Code shall be a prohibited substance
10 only during the season of play. Only a sub-
11 stance or method prohibited out-of-competition
12 by the Anti-Doping Code shall be a prohibited
13 substance or method during the off-season.

14 “(9) SEASON OF PLAY.—

15 “(A) IN GENERAL.—The term ‘season of
16 play’ for each major professional league means
17 the period of time in each calendar year begin-
18 ning with the date on which professional ath-
19 letes of that major professional league are col-
20 lectively obligated to report to their teams in
21 preparation for play and ending with the last
22 game of the major professional league’s regular
23 season.

24 “(B) POST-SEASON.—The season of play
25 shall include post-season play for an athlete



1 who is a member of a team that remains active
2 in post-season play.

3 **“SEC. 724. MINIMUM UNIFORM TESTING STANDARDS.**

4 “(a) CONDUCT PROHIBITED.—It shall be unlawful
5 for a major professional league to arrange, promote, orga-
6 nize, or produce a professional game without meeting the
7 requirements in subsection (b).

8 “(b) MINIMUM TESTING REQUIREMENTS.—Each
9 major professional league shall implement policies and
10 procedures for the testing of the use of prohibited sub-
11 stances by professional athletes who compete in each re-
12 spective major professional league which shall be inde-
13 pendently administered and shall be consistent with and
14 as stringent as the doping control standard established by
15 the United States Anti-Doping Agency, and which shall,
16 at minimum, include the following:

17 “(1) TIMING AND FREQUENCY OF TESTING.—

18 “(A) IN GENERAL.—Each professional ath-
19 lete shall be tested a minimum of 5 times each
20 calendar year that such athlete is competing in
21 games organized by the major professional
22 league.

23 “(B) TIMING.—Each athlete shall be
24 tested—



1 “(i) at least 3 times, each with no ad-
2 vance notice, during each season of play;
3 and

4 “(ii) at least 2 times, each with no ad-
5 vance notice, during the off-season.

6 “(2) TEST DISTRIBUTION PLANNING.—Each
7 major professional league shall certify to the Direc-
8 tor on or prior to December 31 of each year that it
9 has consulted with the United States Anti-Doping
10 Agency in the development of its test distribution
11 plan for both season of play and off-season testing.

12 “(3) METHOD OF TESTING.—Each major pro-
13 fessional league shall certify to the Director on or
14 prior to December 31 of each year that it has con-
15 sulted with the United States Anti-Doping Agency in
16 the development of its drug testing protocols for
17 both season of play and off-season testing.

18 “(4) APPLICABLE SUBSTANCES.—Each profes-
19 sional athlete shall be tested for all prohibited sub-
20 stances at the time of each test. A major profes-
21 sional league may make exceptions for any prohib-
22 ited substances that have been properly prescribed
23 by a doctor of medicine licensed in the United States
24 for legitimate and documented therapeutic purposes.



1 “(5) ANALYSIS OF SAMPLE.—Each sample pro-
2 vided shall be analyzed by a laboratory approved by
3 the United States Anti-Doping Agency.

4 “(6) POSITIVE TESTS.—

5 “(A) IN GENERAL.—A positive test shall
6 consist of the presence in the sample of any
7 prohibited substance or its metabolites or mark-
8 ers, or evidence of the use of a prohibited meth-
9 od, unless that substance was prescribed to the
10 athlete in accordance with paragraph (4).

11 “(B) REFUSAL.—A refusal by a profes-
12 sional athlete to submit to a test or a failure of
13 a professional athlete to submit to a test with-
14 out compelling justification shall also be consid-
15 ered a positive test.

16 “(7) PENALTIES.—

17 “(A) GENERAL RULE.—

18 “(i) FIRST VIOLATION.—Except as
19 provided in subparagraph (B), a profes-
20 sional athlete who tests positive shall be
21 immediately suspended for a minimum of 2
22 years for a first violation. All suspensions
23 shall include a loss of pay for the period of
24 the suspension.



1 “(ii) SECOND VIOLATION.—A second
2 violation shall result in a lifetime ban of
3 the professional athlete from all major pro-
4 fessional leagues.

5 “(B) EXCEPTIONS.—

6 “(i) KNOWLEDGE OF THE ATH-
7 LETE.—A major professional league may
8 impose a lesser penalty than provided in
9 subparagraph (A) or no penalty if the pro-
10 fessional athlete establishes that he did not
11 know or suspect, and could not reasonably
12 have known or suspected even with the ex-
13 ercise of utmost caution, that he had used
14 the prohibited substance.

15 “(ii) ASSISTANCE IN IDENTIFYING
16 VIOLATIONS.—A major professional league
17 may impose a lesser penalty than provided
18 in subparagraph (A) if the professional
19 athlete provides substantial assistance to
20 the major professional league in identifying
21 violations of the league’s drug testing pol-
22 icy by other professional athletes or assist-
23 ance in violations of the league’s drug test-
24 ing policy by any coach, trainer, manager,
25 agent, team staff, official, medical, or



1 other personnel working with or treating
2 professional athletes participating in or
3 preparing for sports competition.

4 “(8) ADJUDICATION.—

5 “(A) CONSULTATION.—Each major profes-
6 sional league shall certify to the Director on or
7 prior to December 31 of each year that it has
8 consulted with the United States Anti-Doping
9 Agency in the development of its adjudication
10 process.

11 “(B) DUE PROCESS.—If a professional
12 athlete tests positive, the professional athlete
13 shall have the right to notice, a fair, timely, and
14 expedited hearing, representation by counsel
15 and appeal.

16 “(C) SUSPENSION.—During the pendency
17 of any proceedings the professional athlete shall
18 be suspended from participating in any profes-
19 sional game.

20 “(9) PUBLIC DISCLOSURE.—

21 “(A) TESTING.—A major professional
22 league shall publicly disclose the identity of any
23 professional player who has tested positive as
24 well as the prohibited substance or prohibited



1 method for which he tested positive not later
2 than 30 days after receiving the test results.

3 “(B) PENALTY.—A major professional
4 league shall publicly disclose the name of any
5 penalized athlete, the penalty imposed, the sub-
6 stance for which the player tested positive, and
7 the reason for the penalty not later than 15
8 days after the final disposition of the player’s
9 case.

10 **“SEC. 725. PROMULGATION OF STANDARDS BY THE DIREC-**
11 **TOR OF THE OFFICE OF NATIONAL DRUG**
12 **CONTROL POLICY.**

13 “(a) IN GENERAL.—The Director shall have the au-
14 thority to promulgate standards that would modify the
15 provisions of section 724 as they apply to an individual
16 major professional league for exceptional circumstances or
17 for other good cause.

18 “(b) EFFECTIVENESS MAINTAINED.—A modification
19 under subsection (a) shall not—

20 “(1) reduce the effectiveness of the standards in
21 eliminating the use of steroids or other performance-
22 enhancing substances in any major professional
23 league; or



1 “(2) diminish the leadership role of the United
2 States in eliminating the use of steroids or other
3 performance-enhancing substances in sports.

4 “(c) INCLUSION OF ADDITIONAL LEAGUES.—The Di-
5 rector may include an additional professional sporting
6 league or the colleges and athletes participating in Divi-
7 sion I or Division II of the NCAA as a major professional
8 league if the Director determines that such additions
9 would prevent the use of performance-enhancing sub-
10 stances by high school, college, or professional athletes.

11 “(d) DELEGATION.—The Director may delegate the
12 administration of this subtitle to any other appropriate
13 agency of the Federal Government.

14 **“SEC. 726. ENFORCEMENT BY THE FEDERAL TRADE COM-**
15 **MISSION.**

16 “(a) UNFAIR OR DECEPTIVE ACTS OR PRACTICES.—
17 A violation of section 724 shall be treated as a violation
18 of section 18 of the Federal Trade Commission Act (15
19 U.S.C. 57a) regarding unfair or deceptive acts or prac-
20 tices.

21 “(b) POWERS OF COMMISSION.—

22 “(1) IN GENERAL.—The Commission shall issue
23 and enforce the regulations for the enforcement of
24 section 724 in the same manner, by the same means,
25 and with the same jurisdiction, powers, and duties



1 as though all applicable terms and provisions of the
2 Federal Trade Commission Act (15 U.S.C. 41 et
3 seq.) were incorporated into and made a part of this
4 subtitle. Any person who violates such regulations
5 shall be subject to the penalties and entitled to the
6 privileges and immunities provided in that Act.

7 “(2) ENHANCED PENALTY FOR VIOLATIONS.—
8 Notwithstanding subsection (a) and the Federal
9 Trade Commission Act, in the case of a person who
10 violates section 724, the Commission may, in its dis-
11 cretion, seek a civil penalty for such violation in an
12 amount, as determined by the Commission, of not
13 more than \$1,000,000 for each violation of section
14 724.

15 “(3) GENERAL AUTHORITY.—Nothing in this
16 subtitle shall be construed to limit the authority of
17 the Commission under any other provision of law.

18 **“SEC. 727. REPORTS TO CONGRESS.**

19 “(a) FIRST LEAGUE REPORT.—

20 “(1) IN GENERAL.—Not later than 6 months
21 after completion of a professional sports league’s
22 first season of play after the effective date of this
23 subtitle, each major professional league shall trans-
24 mit to the Committee on Commerce, Science, and
25 Transportation of the Senate and the Committee on



1 Energy and Commerce and the Committee on Gov-
2 ernment Reform of the House of Representatives, a
3 report on its testing policies and procedures.

4 “(2) CONTENTS.—The report required by this
5 subsection shall contain—

6 “(A) a comparison of the major profes-
7 sional league’s testing policy (including its adju-
8 dication procedures) to that of the United
9 States Anti-Doping Agency, emphasizing the
10 differences between the policies and the ration-
11 ales for the differences; and

12 “(B) aggregate data on the number of pro-
13 fessional players tested by the major profes-
14 sional league and the prohibited substances de-
15 tected in samples or prohibited methods, includ-
16 ing the number of tests conducted during the
17 season of play and during the off-season.

18 “(b) BIENNIAL LEAGUE REPORTS.—Each major pro-
19 fessional league shall transmit to the Committee on Com-
20 merce, Science, and Transportation of the Senate and the
21 Committee on Energy and Commerce and the Committee
22 on Government Reform of the House of Representatives,
23 on a biennial basis, a report containing the data and anal-
24 ysis required in subsection (a) for each of the 2 prior
25 years.



1 substances by college athletes which shall examine the pro-
2 hibited substance policies and testing procedures of inter-
3 collegiate athletic associations and college and university
4 athletic departments.

5 “(b) REPORT.—

6 “(1) SUBMISSION TO CONGRESS.—Not later
7 than 1 year after the date of enactment of this sub-
8 title, the Government Accountability Office shall
9 transmit a report to the Committee on Commerce,
10 Science, and Transportation of the Senate and the
11 Committee on Energy and Commerce and the Com-
12 mittee on Government Reform of the House of Rep-
13 resentatives.

14 “(2) CONTENTS.—The report required by this
15 subsection shall—

16 “(A) assess the adequacy of the testing
17 policies and procedures described in subsection
18 (a) in detecting and preventing the use of per-
19 formance-enhancing substances; and

20 “(B) include recommendations to Congress
21 regarding expanding the application of the reg-
22 ulations issued pursuant to this subtitle to such
23 intercollegiate and interscholastic athletic asso-
24 ciations.



1 **“SEC. 730. COMMISSION ON HIGH SCHOOL AND COLLE-**
2 **GIATE ATHLETICS.**

3 “(a) COMMISSION.—The Director shall establish a
4 commission on high school and collegiate athletics.

5 “(b) REPORT.—Not later than 1 year after the date
6 of enactment of this subtitle, the commission shall report
7 to Congress—

8 “(1) findings on the use of steroids and other
9 performance-enhancing substances in high school
10 and collegiate sports; and

11 “(2) recommendations for reducing their use.

12 **“SEC. 731. SENSE OF CONGRESS.**

13 “It is the sense of Congress that—

14 “(1) professional sports leagues not regulated
15 by this subtitle should adhere to the drug testing
16 standards established in this subtitle;

17 “(2) all professional sports should implement
18 policies and procedures for the testing of the use of
19 prohibited substances or the detection of prohibited
20 methods by professional athletes that ensure that
21 American professional sports leagues are world lead-
22 ers in the effort to keep steroids and other perform-
23 ance-enhancing drugs out of sports;

24 “(3) all professional sports should implement
25 policies and procedures that address the development
26 of designer steroids and emerging methods for



1 doping, including gene doping, that enhance sports
2 performance, are potential or actual health risks,
3 and are contrary to the spirit of the sport; and

4 “(4) each major professional league should
5 produce and publicize public service announcements
6 regarding the health and safety consequences of
7 steroids and other similar performance-enhancing
8 substances on children and teenagers.

9 **“SEC. 732. EFFECTIVE DATE.**

10 “This subtitle shall take effect 1 year after the date
11 of enactment of this subtitle.”.

12 (b) CONFORMING AMENDMENTS.—The Office of Na-
13 tional Drug Control Policy Act of 1998 (Public Law 105-
14 277; 21 U.S.C. 1701 et seq.) is further amended—

15 (1) by striking “title” each place it appears and
16 inserting “subtitle” in—

17 (A) section 701;

18 (B) section 702;

19 (C) section 703(b)(2);

20 (D) section 704(d)(1); and

21 (E) the first and second sentences of sec-
22 tion 705(a)(2)(A); and

23 (2) in section 711(b), by striking “title” and in-
24 serting “Office of National Drug Control Policy Re-
25 authorization Act of 1998”.

